Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytyc

This article was originally published in The Gray Sheet

Executive Summary

Offer to purchase Digene is extended to midnight April 25, with the possibility that the deadline will be further extended. Approximately 10.4 mil. shares of Digene common stock, representing 58% of the total outstanding, have been tendered and not withdrawn pursuant to the offer. Cytyc and Digene each received a formal request for additional information from the Federal Trade Commission following the initial acquisition proposal in mid-February (1"The Gray Sheet" Feb. 25, 2002, p. 3). The firms say they are "responding expeditiously"...

You may also be interested in...



Cytyc Gets Digene After Long Courtship, On Verge Of New Indication

The payback on Cytyc's $554 mil. acquisition of Digene could get a quick boost from Digene's pending primary screening indication for DNA Pap for cervical cancer

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

UsernamePublicRestriction

Register

MT016406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel